Baxter announced the CE marking of the Evo IQ Infusion System. In addition to the planned marketing of the device in the United Kingdom, Ireland and New Zealand, the Evo IQ Infusion System recently received regulatory approval by the Therapeutic Goods Administration (TGA) in Australia. These markets represent the first in a series of planned regulatory submissions for the Evo IQ Infusion System in countries around the world, with commercial launch activities starting in the third quarter of 2018.
The Evo IQ Infusion System features a scalable platform and user-centric design that includes an advanced drug library and dose error reduction software to promote patient safety; intuitive clinical workflows to help optimize clinician efficiency; and Baxter’s One Set technology, which allows clinicians to switch between gravity and pump applications without changing sets, reducing disconnects and set changes and may help reduce opportunities for touch contamination, along with helping to reduce IV tubing use and costs.
“With the Evo IQ Infusion System, Baxter is extending its leading-edge infusion systems technology to help increase drug library compliance and protect patient infusions in the UK, Ireland, Australia, and New Zealand,” said David Ferguson, general manager, Medication Delivery, Baxter. “The Evo IQ Infusion System provides healthcare facilities with access to Baxter’s proven infusion safety technology in an adaptable system that can grow with their needs.”
At launch, the Evo IQ Infusion System will include a large volumetric infusion pump, with a pipeline of complementary technology to launch in the future, including additional pump and set offerings that will enable healthcare facilities to expand and upgrade the Evo IQ platform.